Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071183 · ClinicalTrials.gov registry record · Phase 1
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
A Phase 1 study, sponsored by Turning Point Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05071183 is a Phase 1 study that was terminated before completion, run by Turning Point Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT05071183, a Phase 1 study, was terminated before completion, sponsored by Turning Point Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Interventions
- DRUG Trametinib
- DRUG TPX-0005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071183
The ClinicalTrials.gov registry entry for NCT05071183 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Turning Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trametinib is the first listed.
NCT05071183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05071183 about?
NCT05071183 is a clinical study titled "A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors". A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
What is the current status of trial NCT05071183?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-09-23. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT05071183?
The interventions under investigation include: Trametinib (DRUG), TPX-0005 (DRUG).
Who is sponsoring clinical trial NCT05071183?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.